Table 2.

Representative list of drugs identified using the L1000CDS² search engine of the Library of Integrated Cellular Signature (LINCS) analysis to be predicted to act on Nrf2-dependent lung transcriptome during the bronchopulmonary dysplasia pathogenesis.

Hyperoxia exposure day	Drug name	Activity of compound*	Disease treatment	Minimum overlap ratio	Corresponding p value
day 1	Elesclomol	Induction of cancer cell death by oxidative stress	Anti-cancer activity	0.1765	3.060 × 10−6
1	Isoliquiritigenin	Inhibits NLRP3 inflammasome	Treatment of inflammatory diseases	0.1765	7.170 × 10−7
1/3	Parthenolide	Suppression of apoptotic genes	Anti-cancer and anti- inflammatory activities	0.2059/0.2051	6.280 × 10−6 /9.929 × 10−4
1/3	L-sulforaphane	Induction of Nrf2 and prevent NF-κB binding	Induce detoxification and xenobiotic enzymes	0.1765/0.2051	3.100 × 10−10 /7.32 × 10−5
1/3	Arachidonyl trifluoro- methyl ketone	Inhibits PLA2	Neuroprotective and treatment of multiple	0.1765/0.2564	6.280 × 10−6 7.650 × 10−4
1/3	Parthenolide	Binds directly to and inhibit IKKβ	Anti-inflammatory and anti- hyperalgesic activities	0.2059/0.2051	6.28 × 10−6 /9.929 × 10−4
3	Celastrol	Inhibits NF-κB	Antioxidant, anti- inflammatory, and anti-cancer	0.2308	4.390 × 10−5
3	Canertinib	Tyrosine kinase activity	activities Anti-cancer activity	0.2051	9.010 × 10−6
3	Afatinib	Inhibits EGFR and HER2	Anti-cancer (NSCLC) activity	0.2051	3.042 × 10−4
3	15-delta prostaglandin J2	PPAR-γ agonist	Antioxidant and anti- inflammatory activities	0.2051	1.210 × 10−10

Drugs and chemicals were identified using the L1000CDS² search engine for which there are statistically significant overlap ratios of transcript profiles from cell-based perturbation experiments and Nrf2-dependent lung transcriptome analysis in neonatal mice exposed to hyperoxia. Details for L1000CDS² analyses are described elsewhere [41]. Full list of the drugs and chemicals in Appendix 3.

^*EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; IKKβ, I kappa B kinase beta; NLRP3, NLR Family, Pyrin Domain Containing 3; NSCLC, non-small cell lung cancer; NF-κB; nuclear factor kappa-light-chain-enhancer of activated B cells PLA2, phospholipase 2; PPAR-γ, peroxisome proliferator-activated receptor gamma.